Avatrombopag maleate, a non-peptide oral thrombopoietin receptor agonist (TPO-RA), interacts with the transmembrane domain of human TPO receptors to initiate signal transduction cascades. This stimulates megakaryocyte proliferation and differentiation in the bone marrow, thereby promoting platelet production and release. It is primarily indicated for adult patients with chronic liver disease-associated thrombocytopenia undergoing scheduled diagnostic procedures or surgery.
